Relief of chronic, debilitating, unmerciful and unrelenting pain.
Chemotherapy is a common and universally practiced treatment for many indications of cancer. It is as brutal as it is effective. Its toxic and destructive properties are well known. It is extremely lethal on cancer cells, but unfortunately just as lethal on normal cells.
Under the treatment of chemotherapy agents many patients make excellent progress toward eliminating cancer cells. However, the massive destruction of normal cells and the toll it takes on the patient's overall health frequency requires oncologists to back off on effective dosage levels or eliminate chemotherapy treatment all together. Sadly this almost invariably leads to the continuation and spreading of the cancer.
CCIPN, chronic chemotherapy induced peripheral neuropathy pain is the direct result of chemotherapy destroying nerve endings. This occurs in 30-40 percent of chemotherapy patients. Currently there is no FDA approved treatment for this chronic pain. This pain can be so horrific that it will force oncologist to eliminate effective chemotherapy treatment with subsequent dire consequences for the patients. Our KRN5500 has already demonstrated statistical significant pain reduction for these chemotherapy patients in a Pase II trial.
This is clearly an unmet medical need. Coupled with the fact that the number of these patients are in the 200,000 neighborhood, an FDA requirement, makes it a prime candidate for Orphan Drug status. This status is likely to be granted in the next couple of weeks. That designation will make us an attractive target for a big Pharma partnership or licensing deals.
These are exciting times for DARA shareholders and long suffering CIPN patients.